Published • loading... • Updated
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
Servier will share long-term VORANIGO results and early Emi-Le data, including more than three years of follow-up in IDH-mutant glioma.
- Servier Pharmaceuticals will present new research data at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 through June 2 in Chicago.
- Headquartered in France, the Servier Group invests nearly 20% of its brand-name revenue into research and development, relying on more than 20,000 employees across more than 130 countries.
- Updated long-term data from the Phase 3 INDIGO trial of VORANIGO show sustained progression-free survival and time to next treatment intervention, while demonstrating reduced seizure frequency and preserved quality of life for IDH-mutant glioma patients.
- On June 1, One Biopharmaceuticals, now part of Servier, will share Phase 1 clinical trial results for the investigational compound Emi-Le, showing favorable tolerability and antitumor activity in adenoid cystic carcinoma patients.
- Research updates will follow at the European Hematology Association 2026 Congress in Stockholm, scheduled for June 11 through June 14, extending the group's series of scientific disclosures.
Insights by Ground AI
19 Articles
19 Articles
Bennington Banner+18 Reposted by 18 other sources
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
Updated efficacy and safety data from a long-term analysis of the Phase 3 INDIGO trial of VORANIGO® (vorasidenib) will be presented in a rapid oral presentationResults from an ongoing Phase 1 trial evaluating investigational compound Emi-Le in adenoid cystic carcinoma…
Coverage Details
Total News Sources19
Leaning Left2Leaning Right2Center10Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
